Congressional Pressure Mounts On PBMs, But Skepticism Remains About Near-Term Action

Attention on PBMs with minimal risk of policy change may represent the best of both worlds for pharma, which benefits from another part of the industry taking the heat on drug prices but could stand to lose out financially depending on the PBM reform approaches taken.